anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aging in an individual refers to the temporal change, mostly decline, in the body's ability to meet physiological demands. Biological age (BA) is a biomarker of chronological aging and can be used to stratify populations to predict certain age-related chronic diseases. BA can be predicted from biomedical features such as brain MRI, retinal, or facial images, but the inherent heterogeneity in the aging process limits the usefulness of BA predicted from individual body systems. In this paper, we developed a multimodal Transformer-based architecture with cross-attention which was able to combine facial, tongue, and retinal images to estimate BA. We trained our model using facial, tongue, and retinal images from 11,223 healthy subjects and demonstrated that using a fusion of the three image modalities achieved the most accurate BA predictions. We validated our approach on a test population of 2,840 individuals with six chronic diseases and obtained significant difference between chronological age and BA (AgeDiff) than that of healthy subjects. We showed that AgeDiff has the potential to be utilized as a standalone biomarker or conjunctively alongside other known factors for risk stratification and progression prediction of chronic diseases. Our results therefore highlight the feasibility of using multimodal images to estimate and interrogate the aging process.
The placebo powder consists of maltodextrin and contains no probiotics. Participants will orally take two sachets daily and last for 8 weeks.
The invention belongs to the technical field of medicines, and discloses atenolol gel for treating infantile hemangioma, a preparation method and application thereof, wherein the atenolol gel for treating infantile hemangioma is 5% of atenolol gel. The atenolol gel consists of atenolol and solid gel. The atenolol content per gram of atenolol gel is 50 mg. The preparation method of the atenolol gel comprises the following steps: mixing atenolol 50mg with the fixed gel. The atenolol gel can be used for treating infantile hemangioma, and has the advantages of good treatment effect, less adverse reaction and wider adaptation diseases; the half life is longer, the medicine use frequency is less, the medical adaptability is better, and the price is lower. The atenolol gel disclosed by the invention can be used for treating hemangioma through external application, and can avoid the risks of adverse reactions such as gastrointestinal discomfort (diarrhea), mood change and the like caused by oral administration of a medicament.
The invention relates to the field of traditional Chinese medicine compositions, and more specifically relates to a traditional Chinese medicine composition for treating constipation. The traditional Chinese medicine composition is composed of 10-25 g of angelica sinensis, 10-25 g of radix codonopsis, 5-15 g of fleece-flower root, 15-30 g of fructus cannabis, 5-15 g of bighead atractylodes rhizome, 3-15 g of pericarpium arecae, 8-15 g of fructus aurantii, 5-15 g of glossy privet fruit, 3-10 g of herba cistanche, 10-20 g of radix astragali, 3-10 g of dried orange peel, 2-10 g of cynomorium songaricum, 1-5 g of cortex magnoliae officinalis, 3-15 g of white paeony root and 10-20 g of the licorice root. The traditional Chinese medicine composition has relatively good curative effects for all ages. A curative rate is higher than 83.94%, and can reach as high as 97.08%. An average curative rate is 90.36%. A total effective rate can reach as high as 99.85%. Therefore, the traditional Chinese medicine composition has a significant curative effect for treating constipation, is short in curative period and can cure the constipation in two weeks.
Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an under-appreciated complication of lipid dysmetabolism in type 2 diabetes (T2DM). Although it appears that insulin resistance (IR) is a mechanism common to both, the mechanisms linking IR to unhealthy fat accumulation in liver remains unclear. "Pure" IR would be expected to disinhibit hepatic glucose production while dampening hepatic triglyceride (TG) biosynthesis, but the excessive hepatic de novo lipogenesis (DNL) of IR-associated MASLD suggests that hepatic IR is "selective." However, the concept of IR selectivity is controversial, and because of clinical heterogeneity, lead-time discrepancies, co-morbidities, and medication effects, parsing out this pathophysiologic conundrum in humans is challenging. The investigators plan to test whether the multifactorial IR in patients at risk of T2DM/MASLD is selective by determining if inducing a discrete, "pure" form of IR, via pharmacologic inhibition of phosphoinositide-3-kinase (PI3K) with alpelisib, versus placebo, attenuates excessive DNL. Investigators will also study this question in healthy, insulin-sensitive (IS) volunteers.

Participants in this randomized crossover trial will be admitted twice to the inpatient clinical research unit. During each admission, they will take a dose of either alpelisib or placebo (in randomized order) in the evening and receive infusions of \[13C\] sodium acetate and \[2H\] D-glucose to measure DNL and endogenous glucose production (EGP), respectively, during an overnight fast. DNL measurement will then continue during the following day during 8 hours of standardized mixed-meal feedings. Blood will be drawn at defined intervals for determining levels of glucose, insulin, lipids including triglycerides and free fatty acids, and tracer/tracee enrichments for the stable-isotope tracers. There will be a 2-8-week hiatus for drug washout between the two inpatient study admissions.
Although many schizophrenia patients currently take oral antipsychotic medications, it is estimated that up to 75% of them have difficulty adhering to the daily oral regimen. Long-acting injectable formulations may eliminate the need for daily medication and enhance patient compliance with the treatment regimen. This study is a pilot project to demonstrate that long-acting risperidone can be used safely and effectively in treating patients in the early stage of psychosis. It is an open-label, single-arm study in patients with recent onset of schizophrenia, schizophreniform disorder, or schizoaffective disorder. There are 3 phases: Wash-out Phase of 7 days, during which current psychotropic medications are discontinued; Oral Treatment Phase, beginning 1 week before the first injection and continuing 3 weeks thereafter, during which risperidone tablets are taken; and Long-Acting Injectable Treatment Phase, during which injections are given every 2 weeks for 24 months. Assessments of effectiveness include Positive and Negative Syndrome Scale (PANSS), a scale for the measurement of symptoms of schizophrenia; time from initiation of treatment to relapse; Calgary Depression Scale for Schizophrenia (CDSS), which assesses symptoms of major depressive disorder in patients with schizophrenia; and Clinical Global Impression (CGI) scales. Safety assessments include the incidence of adverse events and Extrapyramidal Symptom Rating Scale (ESRS) scores throughout the study; clinical laboratory tests (hematology and chemistry) and vital signs (pulse, blood pressure, temperature) at stated intervals. Risperidone oral tablets once daily (1 milligram\[mg\], 2mg, or 3mg \[maximum\]) from 1 week before first injection through 3 wks after. Risperidone injections (25mg, 37.5mg, or 50mg \[max\]) every 2 weeks for 24 months. Doses may be increased or decreased at investigator's discretion.
The present invention relates to a traditional Chinese medicine composition for treating menorrhagia and a medicine preparation and a preparation method thereof. The traditional medicine composition comprises garden burnet root, ecliptae herba, cape jasmine fruit, sophora flower, cacumen biotae and cattail pollen, and can also comprise hairyvein agrimonia herd, bistort rhizome, cirsium japonicum, vagina trachycarpi carbonisata, cortex moutan, madder, rehmannia roots, white peony alba, scutellaria and cyrtomium rhizome, and angelica can also be added. The traditional Chinese medicine composition can be made into various clinical dosage forms; at the time of preparation, the methods of alcohol extraction, decoction, etc. are adopted to achieve the full exertion of effective medicines. The medicine of the present invention can enhance the functions of blood coagulation and hemostasis, enhance the constriction action of an isolated uterus and an in-vivo isolated uterus, and participate in the regulation of hormones and periods. A large dose of the medicine of the present invention also has antiinflammatory action.
BACKGROUND: Testosterone deficiency (TD) and obesity are globally recognized health concerns, with a bidirectional causal relationship between them. And a newly discovered obesity indicator, the Weight-Adjusted-Waist Index (WWI), has been proposed, demonstrating superior adiposity identification capability compared to traditional body mass index (BMI) and waist circumference (WC) indicators. Therefore, we present the inaugural investigation into the associations of WWI with total testosterone levels and the risk of TD.
METHODS: Data restricted to the National Health and Nutrition Examination Survey (NHANES) between 2013 and 2016 were analyzed. Only males aged > 20 years who completed body measures and underwent serum sex hormone testing were potentially eligible for analysis. Weighted multivariable linear regression and logistic regression analyses were employed to investigate the relationships between WWI and total testosterone levels, and the risk of TD, respectively. Smooth curve fittings and weighted generalized additive model (GAM) regression were conducted to examine the linear relationship among them. Additionally, subgroup analyses with interaction tests were performed to assess the stability of the results.
RESULTS: Finally, a total of 4099 participants with complete data on testosterone and WWI were included in the formal analysis. The mean age of study participants was 46.74 ± 0.35 years with a TD prevalence of 25.54%. After adjusting all potential confounders, the continuous WWI displayed a negative linear relationship with total testosterone levels (β=-61.41, 95%CI: -72.53, -50.29, P < 0.0001) and a positive linear relationship with risk of TD (OR = 1.88, 95%CI: 1.47, 2.39, P < 0.0001). When WWI was transformed into quartiles as a categorical variable, participants in Q4 exhibited lower total testosterone levels (β=-115.4, 95%CI: -142.34, -88.45, P < 0.0001) and a higher risk of TD (OR = 3.38, 95% CI: 2.10, 5.44, P < 0.001). These associations remained stable in subgroup analyses without significant interaction (all P for interaction > 0.05).
CONCLUSIONS: This investigation firstly unveiled a negative linear association between WWI and total testosterone levels, coupled with a positive linear relationship with the prevalence of TD in U.S. male adults aged 20 years and older. Further studies are needed to validate the potential utility of WWI for the early identification and timely intervention of TD.
Writing skills, crucial for various forms of expression, depend on effective planning and self-regulation. Competent writers emphasise pre-writing activities and self-regulation nevertheless students with Specific Learning Disabilities (SLD) often struggle with writing, impacting their academic achievement. This study explored the efficacy of the STOP and DARE strategy, grounded in the Self-Regulated Strategy Development (SRSD) model, for teaching persuasive writing to four high school students diagnosed with SLD. The study employed a multiple probe across subjects design to assess the impact of STOP and DARE on various persuasive writing skills. The intervention involved rigorous implementation of the strategy over 12-21 sessions, occurring 3 days a week for 80-90 min each day. The results indicated a functional relation between the strategy's implementation and improvements in persuasive essay elements, text length, use of linking words and holistic quality. Moreover, participants expressed a high level of satisfaction with the intervention. Future research could consider investigating functional text elements in addition to basic persuasive text elements. Furthermore, the adaptability of the STOP and DARE strategy to different languages and its applicability in diverse writing types, as well as its effectiveness in varied linguistic and cultural contexts, should be explored.
To investigate current ED management of patients with syncope in Italy and opportunities for optimization, we carried out a questionnaire survey involving 102 directors of ED facilities in our country, of any complexity level, with 55.9% located in the North, 97% equipped with an ED Observation Unit (EDOU), and 21.8% with an outpatient Syncope Unit (SU). 43.6% of EDs management is not standardized. Clinical judgment and monitoring are the main factors leading management while old age and neuropsychic comorbidities the most hindering it. More than one third of ED facilities treats fewer than half of patients in EDOU. Most of respondents (73.7%) reported an admission rate within 20%, primarily in cardiology, in the case of an established or suspected cardiac etiology of syncope. In most centers, the referral to the general practitioner is the priority path at discharge from ED. Nearly 50% of participants rated syncope management in their own center as sub-optimal. To optimize it, 98% of them believe that is appropriate to implement a standardized approach, with and a large majority focusing on increasing diagnostic yield and safety; other priorities include application of guidelines, implementation of care pathways, enhancement of the role of EDOU, and direct path to the SU. This study highlights that the management of syncope patients in our country requires a further improvement, especially through standardization of pathways and adoption of innovative organizational solutions. Admissions appear to be lower than reported in the literature but this finding must be confirmed by a multicentric study based on direct collection of data.
A hair growth and restoration promoter having containing as an active ingredient, an extract drawn from at least one kind of orchidaceae plant selected from a group consisting of Calanthe R. Br.,  Phaius Lour., or other genera having a pseudo bulb.      The promoter is obtained from the subterranean stem of Calanthe discolor Lindl., Phaius flavus (Blume) Lindl. or Oreorchis patens Lindl. through the steps of water washing, slicing, immersion in an aqueous alcohol solution to effect extraction, purification by filtration, addition of vitamins, amino acids, animal and plant oils, sodium chloride and so forth, and appropriate dilution with an aqueous alcohol solution.       When applied to a patient whose hair has badly fallen out or thinned out, or been lost entirely, the promoter promotes hair growth and restoration.
1,182,280. Extracting hydrophilic substances. E.I. DU PONT DE NEMOURS & CO. 12 May, 1967 [16 May, 1966], No. 22087/67. Heading C2C. A process for a hydrophilic substance, particularly adenosine triphosphate, from a material containing the hydrophilic substance bound or sequestered to a water-insoluble substance comprises preparing a mixture of the material with water and an organic liquid extractant, the water being partially soluble in the extractant and the extractant being present in an amount sufficient to dissolve part but not all of the water, whereby there are formed as separate phases an aqueous phase containing the dissolved hydrophilic substance and an organic liquid extractant phase, separating the phases and recovering the aqueous phase. The process is particularly applicable to hydrophilic substances found in living organisms, e.g. nucleotides, nucleosides, flavins or watersoluble cofactors. Specified extractants are 1-butanol, 2-butanol, t-butyl alcohol, n-amyl alcohol, t-amyl alcohol and 3-pentanol, anhydrous 1-butanol being preferred. Example describe the extraction of adenosine triphosphate from a culture of Escheriahia coli.
At present, the molecular mechanisms driving the progression and metastasis of oral squamous cell carcinoma (OSCC) remain largely uncharacterized. The activation of transforming growth factor-β (TGF-β) signaling in the tumor microenvironment has been observed in various types of cancer and has been implicated their progression by enhancing the migration and invasion of epithelial cancer cells. However, its specific roles in the oral cancer progression remain unexplored. In this study, we examined the effects of TGF-β signaling on the murine squamous cell carcinoma, SCCVII cells in vitro and in vivo. The incubation of SCCVII cells with TGF-β induced the activation of TGF-β signals and epithelial-mesenchymal transition (EMT). Notably, the motility of SCCVII cells was increased upon the activation of the TGF-β signaling. RNA sequencing revealed upregulation of genes related to EMT and angiogenesis. Consistent with these in vitro results, the inhibition of TGF-β signals in SCCVII cell-derived primary tumors resulted in suppressed angiogenesis. Furthermore, we identified six candidate factors (ANKRD1, CCBE1, FSTL3, uPA, TSP-1 and integrin β3), whose expression was induced by TGF-β in SCCVII cells, and associated with poor prognosis for patients with head and neck squamous cell carcinoma. These results highlight the role of TGF-β signals in the progression of OSCC via multiple mechanisms, including EMT and angiogenesis, and suggest novel therapeutic targets for the treatment of OSCC.
The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
The invention discloses a Chinese patent medicine for treating irregular menstruation. The Chinese patent medicine consists of the following components in parts by weight: 10-20 parts of fructus rubi, 10-20 parts of radix paeoniae alba, 10-40 parts of raw concha ostreae, 10-20 parts of herba ecliptae, 5-20 parts of cortex ailanthi, 5-20 parts of radix rehmanniae, 2-10 parts of herba leonuri and 2-10 parts of cortex lycii radicis. The product (the Chinese patent medicine) disclosed by the invention has functions of nourishing yin and clearing heat, inducing astringency and solidifying erosion. The product is mainly used for treating preceeded menorrhea, dripping menstruation (menostaxis) and intermenstrual bleeding. The fructus rubi, as a material effective on nourishing yin and inducing astringency, is sweat and sour in property and taste and can enter liver and kidney meridians, and the fructus rubi has effects on strengthening lower energizer and sealing viscera, so as to achieve functions of inducing astringency and astringing yin, sealing and strengthening lower energizer. In the prescription, the radix rehmanniae, the herba ecliptae and the cortex ailanthi have functions of tonifying kidney and nourishing yin, clearing heat and cooling blood, and the cortex lycii radicis, which is sweat, light and cold in property and taste, has functions of solidifying Xuehai point, nourishing yin and clearing heat. The prescription is assisted by the raw concha ostreae which has functions of suppressing yang and inducing astringency, and the raw concha ostreae is salty and slightly cold in property and taste, wherein the salty taste can enter kidney and the cold property can take an effect on clearing heat; and in the prescription, the herba leonuri can be directly applied to the Xuehai point so as to eliminate old tissues and promote generation of new tissues, and in medicines which have functions of strengthening and astringing, the herba leonuri functions as promoting circulation of blood and removing stasis, and regulating supplementary effect of the whole prescription.
Hydrogen pills are mixed in a water glass that is ingested up to 3 times a day for 8 weeks. The hydrogen supplement is intended to reduce oxidative stress and inflammation both of which are implicated in the pathophysiology of chronic fatigue syndrome. This is an 8 week treatment.
Participants in the intervention group will receive a 6-weeks exercise-based intervention with supervised and group-based exercise training three times a week at the hospital setting. Each training session will consist of intermediate and high intensity interval training. The exercise-based intervention will be combined with standard oncological treatments; checkpoint inhibitors, checkpoint inhibitors combined with chemotherapy or oncological surveillance. Additional monitoring of patient will include physical tests, questionnaires and blood samples.
The present invention relates to solid disperser for quickly releasing vitamin A acid. The solid disperser for quickly releasing vitamin A acid loads the vitamin A acid on polyvinylpyrrolidone as a water soluble polymer carrier by a solvent method and a grinding method, and antioxidant is added. Thus, the vitamin A acid is highly dispersed in a strong hydrophilic carrier for improving the dissolution effect of drugs with slight solubility. The solid disperser for quickly releasing vitamin A acid not only can maintain a high dispersed state of the drugs with slight solubility, but also enables the drugs to have good wetting properties. Thus, the solid disperser for quickly releasing vitamin A acid can enhance drug dissolvability, increase drug dissolution speed and increase biological availability. The solid disperser for quickly releasing vitamin A acid of the present invention can be used for preparing cell inducing differentiation drugs and agentia for treating keratoderma abnormality and eye reproduction diseases.